In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says

Executive Summary

A court decision reinstating Teva's generic exclusivity rights for Pravachol will make it more difficult for ANDA filers to predict when a dismissed declaratory judgment action could trigger 180-day exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said Oct. 26

You may also be interested in...



Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?

A recent D.C. federal appeals court decision affirming Teva's exclusivity period for Pravachol generics opens the door for new standard-setting by FDA on what conditions trigger the start of 180-day exclusivity

Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?

A recent D.C. federal appeals court decision affirming Teva's exclusivity period for Pravachol generics opens the door for new standard-setting by FDA on what conditions trigger the start of 180-day exclusivity

Zocor Exclusivity: Ranbaxy Needs Quick Win In Suit Seeking Patent Re-Listing

Ranbaxy needs a relatively quick win in its lawsuit against FDA if it hopes to benefit from the 180-day exclusivity it is claiming for Zocor 80 mg

Related Content

Topics

UsernamePublicRestriction

Register

PS046496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel